63144
document
12-week , placebo-controlled trial of add-on riluzole in the treatment of childhood-onset obsessive-compulsive disorder . Many children with childhood-onset obsessive-compulsive disorder ( OCD ) fail to respond adequately to standard therapies . Evidence from preclinical and clinical studies suggests that the glutamatergic neurotransmitter system might be an alternative treatment target . This study examined the efficacy of riluzole , a glutamatergic modulator , as an adjunctive therapy for children with treatment-resistant OCD . In a 12-week , double-blind , placebo-controlled study , 60 treatment-resistant children and adolescents ( mean age=14.5 ± 2.4 years ) , with moderate to severe OCD ( mean Children 's Yale-Brown Obsessive-Compulsive Scale ( CY-BOCS ) =28.2 ± 3.7 ) , 17 of whom also had concomitant autism spectrum disorder , were randomized to receive riluzole ( final dose of 100 mg/day ) or placebo in addition to the existing treatment regimen . Fifty-nine subjects completed the randomized trial . Primary outcome measures were changes on the CY-BOCS , the Clinical Global Impressions Scale , and the Children 's Global Assessment Scale . Riluzole was fairly well tolerated , although it was associated with one case of pancreatitis and five instances of slight increases in transaminases . All subjects showed significant reductions in CY-BOCS scores during treatment ; however , there was no significant difference between placebo and riluzole on any of the primary or secondary outcome measures . The study failed to demonstrate superiority of riluzole over placebo as an adjunctive treatment for children with childhood-onset OCD . However , future studies may show benefits for less treatment-refractory children with fewer concomitant medications .
63145
Intervention_Control
placebo-controlled
63146
Intervention_Pharmacological
riluzole
63147
Intervention_Pharmacological
riluzole
63148
Intervention_Control
placebo-controlled
63149
Intervention_Pharmacological
riluzole
63150
Intervention_Control
placebo
63151
Participant_Condition
childhood-onset obsessive-compulsive disorder .
63152
Participant_Age
children
63153
Participant_Condition
with childhood-onset obsessive-compulsive disorder ( OCD )
63154
Participant_Age
children
63155
Participant_Condition
with treatment-resistant OCD .
63156
Participant_Sample-size
60 treatment-resistant
63157
Participant_Age
children
63158
Participant_Age
adolescents
63159
Participant_Age
mean age=14.5 ± 2.4 years
63160
Participant_Condition
concomitant autism spectrum disorder
63161
Participant_Sample-size
Fifty-nine
63162
Participant_Age
children
63163
Participant_Condition
childhood-onset OCD
63164
Participant_Condition
concomitant medications